Thermo Fishr Sci - TMO STOCK NEWS

Thermo Fisher Scientific (NYSE: TMO) reported its Q1 2025 financial results with revenue of $10.36 billion, showing minimal growth from $10.34 billion in Q1 2024. The company achieved 1% organic revenue growth and a 15% increase in GAAP EPS to $3.98, while adjusted EPS grew 1% to $5.15.

Key Q1 highlights include the launch of innovative products such as the Vulcan Automated Lab for semiconductor analysis, Olink Reveal proteomics kits, and new centrifuge systems. The company executed significant capital deployment initiatives, including a $4.1 billion agreement to acquire Solventum's Purification & Filtration Business, $2.0 billion in stock repurchases, and a 10% dividend increase.

Operating metrics showed GAAP operating margin of 16.6% (up from 16.1% in Q1 2024) and adjusted operating margin of 21.9% (slightly down from 22.0% in Q1 2024).

Thermo Fisher Scientific (NYSE: TMO) has scheduled its first quarter 2025 financial results announcement for Wednesday, April 23, 2025, before market opening. The company will host a conference call at 8:30 a.m. ET to discuss financial performance and future expectations.

Investors can join the call using the following access details: U.S. participants can dial (833) 470-1428, while international callers should use (404) 975-4839, with access code 074131. The call will also be available via live webcast in the 'Investors' section of thermofisher.com. A replay will remain accessible through May 9, 2025, under the 'News, Events & Presentations' section.

Thermo Fisher Scientific (NYSE: TMO) has unveiled the Thermo Scientific Vulcan™ Automated Lab, a revolutionary solution for semiconductor manufacturing analysis. This integrated system combines robotic handling with AI-enhanced instruments to streamline transmission electron microscopy (TEM) metrology workflows.

The innovation addresses growing demands in semiconductor manufacturing, particularly for atomic-scale TEM metrology data needed in increasingly complex digital technologies. The Vulcan system aims to enhance productivity, increase yield, and reduce operating costs for manufacturers while delivering high-volume, quality data with reduced operator involvement.

The solution specifically targets the time-to-data gap in traditional TEM analysis methods by creating an integrated workflow between semiconductor labs and fabrication facilities through automated materials handling and enhanced data connectivity. The Vulcan Automated Lab is now commercially available.

Solventum (NYSE: SOLV) has announced the sale of its Purification & Filtration business to Thermo Fisher Scientific Inc. (NYSE: TMO) for $4.1 billion. This strategic divestiture is part of phase three of Solventum's transformation plan, aimed at sharpening focus on strategic growth areas and delivering long-term shareholder value.

The transaction is expected to be completed by the end of 2025, subject to regulatory approval and customary closing conditions. Solventum anticipates $3.4 billion in net proceeds, which will be primarily used to pay down debt, strengthening its balance sheet and reducing leverage.

According to CEO Bryan Hanson, this move will enhance Solventum's strategic focus and key metrics while enabling investment in innovation, programs, and talent. The company will discuss the transaction during its upcoming Q4 and full-year 2024 earnings call on February 27, 2025, with an Investor Day scheduled for March 20, 2025.

Thermo Fisher Scientific (NYSE: TMO) has announced a definitive agreement to acquire Solventum's Purification & Filtration business for approximately $4.1 billion in cash. The Solventum business, which generated approximately $1 billion of revenue in 2024, is a leading provider of purification and filtration technologies used in biologics production and other applications.

This acquisition is highly complementary to Thermo Fisher's bioproduction business, expanding its capabilities in biologics development and manufacturing. The transaction is expected to be completed by the end of 2025, subject to regulatory approvals. Once closed, Solventum's business will become part of Thermo Fisher's Life Sciences Solutions segment.

The acquisition is expected to generate mid- to high-single digit organic growth and will be dilutive to adjusted EPS by $0.06 in the first year, but accretive by $0.28 excluding financing costs. Thermo Fisher expects to realize approximately $125 million of adjusted operating income from synergies by year five.

Thermo Fisher Scientific (NYSE: TMO) has announced that Marc N. Casper, chairman, president and chief executive officer, will deliver a presentation at the TD Cowen 45th Annual Health Care Conference. The presentation is scheduled for Monday, March 3, 2025 at 9:10 a.m. ET. Investors and interested parties can access a live webcast of the presentation through the Investors section of Thermo Fisher's website at www.thermofisher.com.

Thermo Fisher Scientific (NYSE: TMO) has announced a 10% increase in its quarterly cash dividend. The company's Board of Directors has authorized a payment of $0.43 per common share, up from the previous $0.39. The dividend will be payable on April 15, 2025, to shareholders of record as of March 14, 2025.

Thermo Fisher Scientific (NYSE:TMO) has announced the election of Karen S. Lynch to its board of directors, effective February 19, 2025. This appointment increases the board's size to 12 members. Lynch, the former president and CEO of CVS Health , brings over three decades of healthcare industry experience. During her tenure at CVS Health, she led more than 300,000 employees and oversaw operations reaching over 120 million consumers through healthcare benefits, pharmacy benefits management, and 9,000+ community health locations.

Lynch's extensive career includes executive positions at Aetna, Magellan Health Services, and Cigna She began her career as a CPA at Ernst & Young LLP and has served on the boards of CVS Health and U.S. Bancorp.

Thermo Fisher Scientific (NYSE: TMO) has announced a 10-year virtual power purchasing agreement (VPPA) with X-ELIO for the Lorca solar project, expected to be operational in early 2026. The company's 73 MW portion will generate approximately 150,000 megawatt-hours of renewable electricity annually, equivalent to powering 40,500 European homes for a year.

This agreement, combined with the previously announced Serbal solar project, will enable TMO to match all its addressable European sites with 100% renewable electricity. The project advances the company's goal of achieving 80% global renewable electricity by 2030. The agreement includes a cohort of pharmaceutical partners (GSK, Gilead Sciences, and Haleon) through the Energize initiative, helping reduce both Scope 2 and Scope 3 emissions.

TMO serves as the cohort lead for this agreement, which aligns with its commitment to reach net-zero emissions by 2050 and its goal to reduce Scope 1 and 2 emissions by 50% by 2030 against a 2018 baseline.